Evidence map›Paper›PMID 39807752›Full record

SynthesisJournal of comparative effectiveness research2025

The burden of Alagille syndrome: uncovering the potential of emerging therapeutics - a comprehensive systematic literature review.

Philip Bufler, Robin Howard, Lucia Quadrado, Guy Lacey, Jolan Terner-Rosenthal, Andrea Goldstein, Pamela Vig, Deirdre Kelly

Abstract readSystematic Review
PubMed Full text at PMC Publisher
In one paragraph

Synthesis in Journal of comparative effectiveness research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Philip BuflerDepartment of Pediatric Gastroenterology, Nephrology & Metabolic Diseases, Charité - Universitätsmedizin Berlin, Berlin, Germany.ORCID 0000-0002-5742-8273
Robin HowardMirum Pharmaceuticals, Inc., Foster City, CA, USA.ORCID 0000-0002-3405-2103
Lucia QuadradoMirum Pharmaceuticals, Inc., Foster City, CA, USA.ORCID 0009-0003-8850-2266
Guy LaceyMirum Pharmaceuticals, Inc., Foster City, CA, USA.ORCID 0009-0008-6048-4074
Jolan Terner-RosenthalMirum Pharmaceuticals, Inc., Foster City, CA, USA.ORCID 0009-0008-0315-3383
Andrea GoldsteinMirum Pharmaceuticals, Inc., Foster City, CA, USA.ORCID 0000-0001-5607-818X
Pamela VigMirum Pharmaceuticals, Inc., Foster City, CA, USA.ORCID 0009-0000-4226-5435
Deirdre KellyGuy's & St Thomas' NHS Foundation Trust, London, UK.ORCID 0000-0001-9776-4354

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

Alagille SyndromeCost of IllnessCholestasisHumansPruritusQuality of LifeAlagille syndromeALGScholestasishealth-related quality of lifepruritus

Identifiers

PMID39807752
PMCPMC11773862

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.